Unknown PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT04425590

The Benefit of Add On DLBS1033 for Ischemic Stroke Patient

The Role of DLBS1033 in the Management of Acute Ischemic Stroke Patients: Study Protocol for a Randomized Controlled Study

Sponsor: Dexa Laboratories Of Biomolecular Science

Conditions Ischemic Stroke

Interventions Aspirin DLBS1033 Statin Vit B12

Updated 5 times since 2020 Last updated: Jun 7, 2020 Started: Apr 1, 2020 Primary completion: Aug 31, 2020 Completion: Aug 31, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04425590, this PHASE2/PHASE3 trial focuses on Ischemic Stroke and remains ongoing. Sponsored by Dexa Laboratories Of Biomolecular Science, it has been updated 5 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2/PHASE3

Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jul 2022 — Jul 2024 [monthly]

Unknown Status PHASE2_PHASE3

Status: Recruiting → Unknown Status
Jan 2021 — Jul 2022 [monthly]

Recruiting PHASE2_PHASE3
Jul 2020 — Jan 2021 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Apr 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dexa Laboratories Of Biomolecular Science
Duta Wacana Christian University

Data source: Duta Wacana Christian University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Yogyakarta, Indonesia